The road less travelled: The efficacy of canine pluripotent stem cells

Dhanya V. Menon, Darshan Patel, Chaitanya G. Joshi, Anujith Kumar

Research output: Contribution to journalReview article

Abstract

The path-breaking discovery of induced pluripotent stem cells has fuelled the scientific advancements of stem cells. Nevertheless, the need to ensure the safety of stem cell therapy at translational level is still at large, prompting scientists to use animal models which are genetically and anatomically homologous to that of humans. Dogs, being genomically and physiologically more similar to humans serve as better models in mimicking human diseases as compared to rodents. The heterogeneity in canine breeds offers an excellent opportunity to comprehend the complexities of many genetic diseases, making them exceptional tools for stem cell therapies. Various canine gene therapy models have paved the foundation for strategizing therapies for humans. But a similar progress is lacking in utilizing canine stem cells for stem cell-based therapies in both dogs and humans. This review attempts to bridge the gap, by articulating the key differences in canine pluripotency pathways, based on the recent derivation of canine embryonic stem cells (cESCs) and canine induced pluripotent stem cells (ciPSCs), thereby attempting to position dog in the reprogramming landscape. The potential clinical application of canine iPSCs also offers great hope to canine patients and might lead to significant contributions in veterinary medicine.

Original languageEnglish
Pages (from-to)94-102
Number of pages9
JournalExperimental Cell Research
Volume377
Issue number1-2
DOIs
Publication statusPublished - 15-04-2019

Fingerprint

Pluripotent Stem Cells
Canidae
Stem Cells
Cell- and Tissue-Based Therapy
Induced Pluripotent Stem Cells
Dogs
Inborn Genetic Diseases
Veterinary Medicine
Embryonic Stem Cells
Genetic Therapy
Rodentia
Animal Models
Safety

All Science Journal Classification (ASJC) codes

  • Cell Biology

Cite this

Menon, Dhanya V. ; Patel, Darshan ; Joshi, Chaitanya G. ; Kumar, Anujith. / The road less travelled : The efficacy of canine pluripotent stem cells. In: Experimental Cell Research. 2019 ; Vol. 377, No. 1-2. pp. 94-102.
@article{be2d1680b90a48a8b4e870c3d003a983,
title = "The road less travelled: The efficacy of canine pluripotent stem cells",
abstract = "The path-breaking discovery of induced pluripotent stem cells has fuelled the scientific advancements of stem cells. Nevertheless, the need to ensure the safety of stem cell therapy at translational level is still at large, prompting scientists to use animal models which are genetically and anatomically homologous to that of humans. Dogs, being genomically and physiologically more similar to humans serve as better models in mimicking human diseases as compared to rodents. The heterogeneity in canine breeds offers an excellent opportunity to comprehend the complexities of many genetic diseases, making them exceptional tools for stem cell therapies. Various canine gene therapy models have paved the foundation for strategizing therapies for humans. But a similar progress is lacking in utilizing canine stem cells for stem cell-based therapies in both dogs and humans. This review attempts to bridge the gap, by articulating the key differences in canine pluripotency pathways, based on the recent derivation of canine embryonic stem cells (cESCs) and canine induced pluripotent stem cells (ciPSCs), thereby attempting to position dog in the reprogramming landscape. The potential clinical application of canine iPSCs also offers great hope to canine patients and might lead to significant contributions in veterinary medicine.",
author = "Menon, {Dhanya V.} and Darshan Patel and Joshi, {Chaitanya G.} and Anujith Kumar",
year = "2019",
month = "4",
day = "15",
doi = "10.1016/j.yexcr.2019.01.025",
language = "English",
volume = "377",
pages = "94--102",
journal = "Experimental Cell Research",
issn = "0014-4827",
publisher = "Academic Press Inc.",
number = "1-2",

}

The road less travelled : The efficacy of canine pluripotent stem cells. / Menon, Dhanya V.; Patel, Darshan; Joshi, Chaitanya G.; Kumar, Anujith.

In: Experimental Cell Research, Vol. 377, No. 1-2, 15.04.2019, p. 94-102.

Research output: Contribution to journalReview article

TY - JOUR

T1 - The road less travelled

T2 - The efficacy of canine pluripotent stem cells

AU - Menon, Dhanya V.

AU - Patel, Darshan

AU - Joshi, Chaitanya G.

AU - Kumar, Anujith

PY - 2019/4/15

Y1 - 2019/4/15

N2 - The path-breaking discovery of induced pluripotent stem cells has fuelled the scientific advancements of stem cells. Nevertheless, the need to ensure the safety of stem cell therapy at translational level is still at large, prompting scientists to use animal models which are genetically and anatomically homologous to that of humans. Dogs, being genomically and physiologically more similar to humans serve as better models in mimicking human diseases as compared to rodents. The heterogeneity in canine breeds offers an excellent opportunity to comprehend the complexities of many genetic diseases, making them exceptional tools for stem cell therapies. Various canine gene therapy models have paved the foundation for strategizing therapies for humans. But a similar progress is lacking in utilizing canine stem cells for stem cell-based therapies in both dogs and humans. This review attempts to bridge the gap, by articulating the key differences in canine pluripotency pathways, based on the recent derivation of canine embryonic stem cells (cESCs) and canine induced pluripotent stem cells (ciPSCs), thereby attempting to position dog in the reprogramming landscape. The potential clinical application of canine iPSCs also offers great hope to canine patients and might lead to significant contributions in veterinary medicine.

AB - The path-breaking discovery of induced pluripotent stem cells has fuelled the scientific advancements of stem cells. Nevertheless, the need to ensure the safety of stem cell therapy at translational level is still at large, prompting scientists to use animal models which are genetically and anatomically homologous to that of humans. Dogs, being genomically and physiologically more similar to humans serve as better models in mimicking human diseases as compared to rodents. The heterogeneity in canine breeds offers an excellent opportunity to comprehend the complexities of many genetic diseases, making them exceptional tools for stem cell therapies. Various canine gene therapy models have paved the foundation for strategizing therapies for humans. But a similar progress is lacking in utilizing canine stem cells for stem cell-based therapies in both dogs and humans. This review attempts to bridge the gap, by articulating the key differences in canine pluripotency pathways, based on the recent derivation of canine embryonic stem cells (cESCs) and canine induced pluripotent stem cells (ciPSCs), thereby attempting to position dog in the reprogramming landscape. The potential clinical application of canine iPSCs also offers great hope to canine patients and might lead to significant contributions in veterinary medicine.

UR - http://www.scopus.com/inward/record.url?scp=85062075298&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85062075298&partnerID=8YFLogxK

U2 - 10.1016/j.yexcr.2019.01.025

DO - 10.1016/j.yexcr.2019.01.025

M3 - Review article

C2 - 30796892

AN - SCOPUS:85062075298

VL - 377

SP - 94

EP - 102

JO - Experimental Cell Research

JF - Experimental Cell Research

SN - 0014-4827

IS - 1-2

ER -